CorpDev.Org
Daily News for Dealmakers
Big Deal
Japan-US Steel Deal: Diplomacy Amid Concerns and Global Dynamics
Diplomatic Efforts: Japan's Prime Minister urged the U.S. President to address concerns over the blocked Nippon Steel-U.S. Steel deal, highlighting the strong opposition from business communities in both nations. Strategic Investments: Japanese...
DOJ Blocks Amex GBT’s $570M CWT Buyout Over Antitrust Concerns
Antitrust Lawsuit: The U.S. Department of Justice has filed a civil antitrust lawsuit to block American Express Global Business Travel's (GBT) proposed $570 million acquisition of rival CWT, citing concerns over reduced competition and higher...
UK Financial Services M&A Skyrockets in 2024: EY Report Shows Record Deal Volume and Value
Record-Breaking Volume: UK financial services M&A activity hit a decade-high of 380 deals in 2024, up 26% from 2023, with total deal value soaring to £20.2 billion. Wealth Management Boom: The wealth and asset management sector led the surge, with...
Johnson & Johnson Eyes $10B Neuroscience Drugmaker Acquisition: Strategic Move Amidst Market Growth
Strategic Alignment: The acquisition aligns Intra-Cellular's neuroscience pipeline with J&J's pharmaceutical offerings, positioning J&J for growth in the $48B neuroscience market. Market Potential: Rising prevalence of neurological disorders like...
Trump 2025: Deregulation Fuels Breakout Mergers & Acquisitions
Deregulation Catalyst: A potential Trump presidency in 2025 could significantly boost M&A activity, driven by anticipated deregulation initiatives and a more business-friendly regulatory environment. Historical Precedents: Past periods of...
Top Jobs Currently Hiring
Private Equity
International
Tech, Media & Telecom
Financial Services
Health & Life Sciences
Eli Lilly’s Potential Acquisition of Scorpion Therapeutics: A Strategic Shift Amid Market Volatility
Strategic Acquisition: Eli Lilly's potential acquisition of Scorpion Therapeutics signals a strategic move to bolster its oncology pipeline and enhance innovation capabilities. Biotech Market Dynamics: The biotech sector is marked by volatility,...
Biogen Bids for Sage Therapeutics: Boosting Neuroscience & Psychiatric Treatments
Strategic Rationale: Biogen's bid to acquire Sage Therapeutics' remaining stake aligns with its long-term strategy to expand neuroscience capabilities and strengthen its psychiatric and neurological disorder portfolio. Pipeline Integration: Sage's...
GSK Acquires IDRx for $1.15B: A Precision Leap in GI Cancer Therapy
Strategic Expansion: GSK's $1.15B acquisition of IDRx bolsters its gastrointestinal (GI) cancer therapy portfolio, marking a significant expansion into the oncology market. Financial Details: The deal includes a $1B upfront payment and potential...
Johnson & Johnson Eyes $10B Neuroscience Drugmaker Acquisition: Strategic Move Amidst Market Growth
Strategic Alignment: The acquisition aligns Intra-Cellular's neuroscience pipeline with J&J's pharmaceutical offerings, positioning J&J for growth in the $48B neuroscience market. Market Potential: Rising prevalence of neurological disorders like...
CVC Capital Partners Aims for €700M Boost in Italian Pharma Outsourcing Giant Genetic: A Market Shift Analysis
Strategic Investment: CVC Capital Partners targets €700 million fundraising for Genetic, a leading Italian pharmaceutical outsourcing company, to drive organic and inorganic growth. Industry Landscape: The Italian pharmaceutical outsourcing...
